Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Patients suffering from diabetic foot have significantly impaired cognitive function

Patients suffering from diabetic foot have significantly impaired cognitive function

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

IQWiG: Benefit of proteome analysis for detection of diabetic nephropathy remains unclear

IQWiG: Benefit of proteome analysis for detection of diabetic nephropathy remains unclear

T1DM therapeutics market expected to reach $7.1 billion by 2021

T1DM therapeutics market expected to reach $7.1 billion by 2021

Breastfeeding may offer unique benefits to women, protect against type 2 diabetes after delivery

Breastfeeding may offer unique benefits to women, protect against type 2 diabetes after delivery

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

Gestational diabetes mellitus screening provides more health benefits to pregnant women

Gestational diabetes mellitus screening provides more health benefits to pregnant women

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Diabetes prevention begins in the womb

Diabetes prevention begins in the womb

New funding for Centenary's life saving research

New funding for Centenary's life saving research

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Understanding molecular mechanisms underlying human aging

Understanding molecular mechanisms underlying human aging

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

Women with Type 2 diabetes face barrier to physical activity

Women with Type 2 diabetes face barrier to physical activity

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Bariatric surgery results in substantial weight loss in overweight children with Prader-Willi syndrome

Bariatric surgery results in substantial weight loss in overweight children with Prader-Willi syndrome

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.